(lp0
S"Better Buy: PDL BioPharma, Inc. vs. Johnson &amp; Johnson Motley Fool - Feb 27, 2017 Biotech finance specialist PDL Biopharma  has been suffering a prolonged market thrashing that's driven its stock price down about 75% over the past three years.PDL BioPharma, Inc.  shows monthly volitility of 3.49% - The Newburgh PressStock Returns: Cytokinetics, Incorporated  versus PDL BioPharma ... - CML News"
p1
aS'PDL BioPharma to Present at Two Upcoming Investor Conferences PR Newswire  - Mar 2, 2017 PDL has committed over $1.4 billion and funded approximately $1.1 billion in these investments to date. PDL is headquartered in Incline Village, Nevada.PDL BioPharma Inc.: PDL BioPharma to Present at Two Upcoming Investor Conferences - The Wall Street TranscriptPDL BioPharma reports 4Q loss - Yahoo Finance'
p2
aS"Can PDL BioPharma, Inc. Turn Things Around? Motley Fool - Oct 28, 2016 In 18 months, PDL BioPharma, Inc.  has lost roughly half of its market cap. The slide wasn't unexpected: Investors have known for a long time that PDL BioPharma's core patents would expire at the end of 2014."
p3
aS"Why PDL BioPharma Inc. Is Down 14.8% Today Motley Fool - Nov 23, 2016 Shares in PDL BioPharma  are tumbling 14.8% at 12:30 p.m. EST Wednesday after management closed on a $150 million convertible notes offering and Eli Lilly &amp; Co.Company Update : Here's Why PDL BioPharma Inc Shares Are Slumping ... - Smarter Analyst"
p4
aS'PDL BioPharma, Inc. Is Off 10% in 2016, and This Is a Big Reason Why Motley Fool - Jun 20, 2016 What: Shares of PDL BioPharma , a small-cap biotech company that invests in patents and royalty-based biotechnology and pharmaceutical assets, has lost 10% of its value so far this year, according to data from S&amp;P Global Market&nbsp;...'
p5
aS"Here's Why PDL BioPharma Inc. Imploded and Fell 32% in November Motley Fool - Dec 2, 2016 Shares of PDL BioPharma , a biotech royalty company, imploded in November and lost 32% of their value according to data from S&amp;P Global Market Intelligence."
p6
aS"PDL BioPharma to Present at the Oppenheimer 27th Annual Healthcare Conference Yahoo Finance - Mar 14, 2017 INCLINE VILLAGE, Nev., March 14, 2017 /PRNewswire/ -- PDL BioPharma, Inc.   today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at the Oppenheimer 27th Annual Healthcare Conference next&nbsp;...ROE of PDL BioPharma, Inc.  stands at 8.5 - TopChronicle"
p7
aS"PDL BioPharma to Announce Fourth Quarter / Year-End 2016 Financial Results on ... PR Newswire  - Feb 22, 2017 INCLINE VILLAGE, Nev., Feb. 22, 2017 /PRNewswire/ -- PDL BioPharma, Inc.   today announced that the Company will release its fourth quarter, year-end 2016 financial results for the period ended December 31, 2016,&nbsp;...Analyst's Indicator Review for DSW Inc. , PDL BioPharma, Inc.  - The USA CommercePDL BioPharma, Inc.  to Release Quarterly Earnings on Thursday - The Cerbat Gem"
p8
aS'PDL BioPharma: 2017 Could Be A Game-Changer Seeking Alpha - Mar 3, 2017 PDLI is a unique company in the biotech world. Traditionally, their business revolved primarily around purchasing income generating assets in the biotech sector, such as patents or providing debt structures for biotech firms at high interest rates.'
p9
aS"PDL BioPharma to Present at the 2017 RBC Capital Markets Global Healthcare ... PR Newswire  - Feb 16, 2017 INCLINE VILLAGE, Nev., Feb. 17, 2017 /PRNewswire/ -- PDL BioPharma, Inc.   today announced that John P. McLaughlin, PDL's president and chief executive officer, will participate in a fireside chat at the 2017 RBC Capital Markets&nbsp;...Movers of most recent trading session: PDL BioPharma, Inc. (NASDAQ:PDLI ... - FactsReporterDividend Growth of PDL BioPharma, Inc. - Highland Mirror"
p10
a.